217 related articles for article (PubMed ID: 15208680)
1. B-RAF is a therapeutic target in melanoma.
Karasarides M; Chiloeches A; Hayward R; Niculescu-Duvaz D; Scanlon I; Friedlos F; Ogilvie L; Hedley D; Martin J; Marshall CJ; Springer CJ; Marais R
Oncogene; 2004 Aug; 23(37):6292-8. PubMed ID: 15208680
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Adnane L; Trail PA; Taylor I; Wilhelm SM
Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
[TBL] [Abstract][Full Text] [Related]
3. B-Raf kinase inhibitors for cancer treatment.
Li N; Batt D; Warmuth M
Curr Opin Investig Drugs; 2007 Jun; 8(6):452-6. PubMed ID: 17621874
[TBL] [Abstract][Full Text] [Related]
4. RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells.
Fan F; Feng L; He J; Wang X; Jiang X; Zhang Y; Wang Z; Chen Y
Carcinogenesis; 2008 Jun; 29(6):1157-63. PubMed ID: 18515281
[TBL] [Abstract][Full Text] [Related]
5. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
6. B-RAF: A contributor to the melanoma phenotype.
Heath EM; Kaufman KL; Christopherson RI
Int J Biochem Cell Biol; 2011 Jan; 43(1):29-32. PubMed ID: 20883818
[TBL] [Abstract][Full Text] [Related]
7. The role of B-RAF in melanoma.
Gray-Schopfer VC; da Rocha Dias S; Marais R
Cancer Metastasis Rev; 2005 Jan; 24(1):165-83. PubMed ID: 15785879
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
Calleros L; Sánchez-Hernández I; Baquero P; Toro MJ; Chiloeches A
Carcinogenesis; 2009 Oct; 30(10):1670-7. PubMed ID: 19700418
[TBL] [Abstract][Full Text] [Related]
9. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation.
Wellbrock C; Marais R
J Cell Biol; 2005 Aug; 170(5):703-8. PubMed ID: 16129781
[TBL] [Abstract][Full Text] [Related]
10. Is B-Raf a good therapeutic target for melanoma and other malignancies?
Madhunapantula SV; Robertson GP
Cancer Res; 2008 Jan; 68(1):5-8. PubMed ID: 18172288
[TBL] [Abstract][Full Text] [Related]
11. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
14. MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation.
Chadee DN; Kyriakis JM
Nat Cell Biol; 2004 Aug; 6(8):770-6. PubMed ID: 15258589
[TBL] [Abstract][Full Text] [Related]
15. Raf: a strategic target for therapeutic development against cancer.
Beeram M; Patnaik A; Rowinsky EK
J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185
[TBL] [Abstract][Full Text] [Related]
16. Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF.
Christensen C; Guldberg P
Oncogene; 2005 Sep; 24(41):6292-302. PubMed ID: 16007203
[TBL] [Abstract][Full Text] [Related]
17. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment.
Meier F; Busch S; Lasithiotakis K; Kulms D; Garbe C; Maczey E; Herlyn M; Schittek B
Br J Dermatol; 2007 Jun; 156(6):1204-13. PubMed ID: 17388918
[TBL] [Abstract][Full Text] [Related]
18. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
Yeh AH; Bohula EA; Macaulay VM
Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
[TBL] [Abstract][Full Text] [Related]
19. Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines.
Lee J; Kim H; Yu H; Chung JY; Oh CH; Yoo KH; Sim T; Hah JM
Bioorg Med Chem Lett; 2010 Mar; 20(5):1573-7. PubMed ID: 20149658
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
